A Phase II Trial Of Arsenic Trioxide (TRISENOX) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Upon determination of eligibility, patients will receive:
- Arsenic Trioxide
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall response rate
John D. Hainsworth, MD
Principal Investigator
Sarah Cannon Research Institute
United States: Food and Drug Administration
SCRI LYM 33
NCT00193518
April 2004
April 2006
Name | Location |
---|---|
Tennessee Oncology, PLLC | Clarksville, Tennessee 37043 |